Revakinagene taroretcel - Neurotech USA
Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; RexenusLatest Information Update: 24 Jun 2024
At a glance
- Originator Neurotech USA
- Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
- Class Cell therapies; Eye disorder therapies; Gene therapies
- Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Retinal telangiectasis
- Phase II/III Retinitis pigmentosa
- Phase II Glaucoma; Usher syndromes
- Phase I/II Colour vision defects
- No development reported Dry macular degeneration; Optic nerve disorders
Most Recent Events
- 20 Jun 2024 Preregistration for Retinal telangiectasis in USA (Intraocular)
- 20 Jun 2024 FDA assigns PDUFA action date of (17/12/2024) for revakinagene taroretcel for Retinal telangiectasis
- 20 Jun 2024 Neurotech Pharmaceuticals receives priority review of Biologics License Application (BLA) for revakinagene taroretcel for Retinal telangiectasis